Amgen entered 2020 with a conservative financial outlook, but that did nothing to dampen expectations for continued acquisitions. The company reported declines in sales and net income in 2019, but results beat analyst estimates, and shares recovered from a brief slump in the first days of February. Its guidance for fiscal 2020 fell short of…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
